Citius Pharmaceuticals, Inc. (CTXR)
NASDAQ: CTXR · Real-Time Price · USD
0.7706
-0.0418 (-5.15%)
At close: Mar 20, 2026, 4:00 PM EDT
0.7860
+0.0154 (2.00%)
After-hours: Mar 20, 2026, 6:37 PM EDT
Citius Pharmaceuticals Employees
Citius Pharmaceuticals had 23 employees as of September 30, 2025. The number of employees did not change compared to the previous year.
Employees
23
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$171,483
Profits / Employee
-$1,560,280
Market Cap
17.24M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2025 | 23 | 0 | - |
| Sep 30, 2024 | 23 | 1 | 4.55% |
| Sep 30, 2023 | 22 | 1 | 4.76% |
| Sep 30, 2022 | 21 | 6 | 40.00% |
| Sep 30, 2021 | 15 | 5 | 50.00% |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Daré Bioscience | 23 |
| IN8bio | 17 |
| FibroBiologics | 15 |
| Traws Pharma | 7 |
| Allarity Therapeutics | 7 |
| Artelo Biosciences | 7 |
| Lexaria Bioscience | 7 |
| Intensity Therapeutics | 7 |
CTXR News
- 11 days ago - Citius Oncology Announces Positive Topline Results from Investigator‑Initiated Phase 1 Study of LYMPHIR™ in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers - PRNewsWire
- 17 days ago - Citius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR™ (E7777) Dosing Prior to Commercial CAR‑T Therapy in High‑Risk Diffuse Large B‑Cell Lymphoma - PRNewsWire
- 25 days ago - Citius Pharmaceuticals, Inc. Secures $3.8 million through New Jersey Economic Development Program - PRNewsWire
- 5 weeks ago - Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™ - PRNewsWire
- 5 weeks ago - Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™ - PRNewsWire
- 5 weeks ago - Citius Oncology Expands International Distribution of LYMPHIR™ to European Union Through Exclusive Agreement with Uniphar - PRNewsWire
- 3 months ago - Stock Market Today: Dow Jones, S&P 500 Futures Drop On Christmas Eve Despite Strong Q3 GDP Report—UiPath, AST SpaceMobile, Ramaco Resources In Focus - Benzinga
- 3 months ago - Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update - PRNewsWire